CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 82 enrolled
Drug / intervention
clomiphene citrate +1 moredrug
Likely dose
clomiphene citrate 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00427700
NCT00427700Phase 3Completed
CompareCT.gov

Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome

Hospital de Clinicas de Porto Alegre·interventional·Posted Jan 29, 2007·Updated Aug 21, 2024

In Brief

A Phase 3 clinical trial evaluating clomiphene citrate and raloxifene for Polycystic Ovary Syndrome. Completed, enrolled 82 participants across 1 site.

Detailed Summary

The Polycystic Ovarian Syndrome (PCOS) is a common disorder related to ovulation problems. Clomiphene citrate (CC) is the drug of first choice for this condition. Nevertheless, CC has a detrimental effect over uterine receptivity. Raloxifene is a Selective Estrogen Receptor Modulator, that does not have a detrimental effect over the endometrium, and also increase the serum levels of FSH, thus, inducting ovulation. The objective of this study is to compare the ovulation rate in PCOS patients between clomiphene citrate and raloxifene in a double blind randomized trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 29, 2007
Enrollment StartAug 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.4 years ago

Interventions

clomiphene citratedrug

100mg PO on days 5-9 of the menstrual cycle

raloxifenedrug

100mg PO on days 5-9 of the menstrual cycle